Differential Expression of Apoptotic Genes PDIA3 and MAP3K5 Distinguishes Between Low- and High-risk Prostate Cancer

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2009 Dec 29

PMID 20035634

Citations 41

Authors

Nicole Chui Pressinotti

Helmut Klocker

Georg Schafer

Van-Duc Luu

Markus Ruschhaupt

Ruprecht Kuner

Eberhard Steiner

Annemarie Poustka

Georg Bartsch

Holger Sultmann

Affiliations

Soon will be listed here.

Abstract

Background: Despite recent progress in the identification of genetic and molecular alterations in prostate cancer, markers associated with tumor progression are scarce. Therefore precise diagnosis of patients and prognosis of the disease remain difficult. This study investigated novel molecular markers discriminating between low and highly aggressive types of prostate cancer.

Results: Using 52 microdissected cell populations of low- and high-risk prostate tumors, we identified via global cDNA microarrays analysis almost 1200 genes being differentially expressed among these groups. These genes were analyzed by statistical, pathway and gene enrichment methods. Twenty selected candidate genes were verified by quantitative real time PCR and immunohistochemistry. In concordance with the mRNA levels, two genes MAP3K5 and PDIA3 exposed differential protein expression. Functional characterization of PDIA3 revealed a pro-apoptotic role of this gene in PC3 prostate cancer cells.

Conclusions: Our analyses provide deeper insights into the molecular changes occurring during prostate cancer progression. The genes MAP3K5 and PDIA3 are associated with malignant stages of prostate cancer and therefore provide novel potential biomarkers.

Citing Articles

Analysis of Punicalin and Punicalagin Interaction with PDIA3 and PDIA1.

Meschiari G, Minacori M, Fiorini S, Tedesco M, Eufemi M, Altieri F Int J Mol Sci. 2024; 25(19).

PMID: 39408858 PMC: 11476419. DOI: 10.3390/ijms251910531.

Transcriptome-wide association analysis identifies candidate susceptibility genes for prostate-specific antigen levels in men without prostate cancer.

Chen D, Dong R, Kachuri L, Hoffmann T, Jiang Y, Berndt S HGG Adv. 2024; 5(3):100315.

PMID: 38845201 PMC: 11262184. DOI: 10.1016/j.xhgg.2024.100315.

Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression.

Schafer C, Jiang J, Elsamanoudi S, Nousome D, Young D, Song Y Cancer Res Commun. 2023; 3(8):1423-1434.

PMID: 37534375 PMC: 10392708. DOI: 10.1158/2767-9764.CRC-22-0463.

Construction and validation of an oxidative-stress-related risk model for predicting the prognosis of osteosarcoma.

Wang H, Li J, Li X Aging (Albany NY). 2023; 15(11):4820-4843.

PMID: 37285835 PMC: 10292890. DOI: 10.18632/aging.204764.

Transcriptome-Wide Association Analysis Identifies Novel Candidate Susceptibility Genes for Prostate-Specific Antigen Levels in Men Without Prostate Cancer.

Chen D, Dong R, Kachuri L, Hoffmann T, Jiang Y, Berndt S medRxiv. 2023; .

PMID: 37205487 PMC: 10187439. DOI: 10.1101/2023.05.04.23289526.

References

Tomlins S, Mehra R, Rhodes D, Cao X, Wang L, Dhanasekaran S . Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2006; 39(1):41-51. DOI: 10.1038/ng1935. View

Igney F, Krammer P . Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002; 2(4):277-88. DOI: 10.1038/nrc776. View

Das S, Hahn Y, Nagata S, Willingham M, Bera T, Lee B . NGEP, a prostate-specific plasma membrane protein that promotes the association of LNCaP cells. Cancer Res. 2007; 67(4):1594-601. DOI: 10.1158/0008-5472.CAN-06-2673. View

Al-Shahrour F, Diaz-Uriarte R, Dopazo J . FatiGO: a web tool for finding significant associations of Gene Ontology terms with groups of genes. Bioinformatics. 2004; 20(4):578-80. DOI: 10.1093/bioinformatics/btg455. View

Bussey K, Kane D, Sunshine M, Narasimhan S, Nishizuka S, Reinhold W . MatchMiner: a tool for batch navigation among gene and gene product identifiers. Genome Biol. 2003; 4(4):R27. PMC: 154578. DOI: 10.1186/gb-2003-4-4-r27. View

Welsh J, Sapinoso L, Su A, Kern S, Wang-Rodriguez J, Moskaluk C . Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 2001; 61(16):5974-8. View

Matsuzawa A, Saegusa K, Noguchi T, Sadamitsu C, Nishitoh H, Nagai S . ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat Immunol. 2005; 6(6):587-92. DOI: 10.1038/ni1200. View

Ni M, Lee A . ER chaperones in mammalian development and human diseases. FEBS Lett. 2007; 581(19):3641-51. PMC: 2040386. DOI: 10.1016/j.febslet.2007.04.045. View

Cooper C, Campbell C, Jhavar S . Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer. Nat Clin Pract Urol. 2007; 4(12):677-87. DOI: 10.1038/ncpuro0946. View

10.

Boer J, Huber W, Sultmann H, Wilmer F, von Heydebreck A, Haas S . Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res. 2001; 11(11):1861-70. PMC: 311168. DOI: 10.1101/gr.184501. View

11.

Takeda K, Noguchi T, Naguro I, Ichijo H . Apoptosis signal-regulating kinase 1 in stress and immune response. Annu Rev Pharmacol Toxicol. 2007; 48:199-225. DOI: 10.1146/annurev.pharmtox.48.113006.094606. View

12.

Ichijo H, Nishida E, Irie K, Ten Dijke P, Saitoh M, Moriguchi T . Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science. 1997; 275(5296):90-4. DOI: 10.1126/science.275.5296.90. View

13.

Iriyama T, Takeda K, Nakamura H, Morimoto Y, Kuroiwa T, Mizukami J . ASK1 and ASK2 differentially regulate the counteracting roles of apoptosis and inflammation in tumorigenesis. EMBO J. 2009; 28(7):843-53. PMC: 2670860. DOI: 10.1038/emboj.2009.32. View

14.

Joshi B, Li L, Taffe B, Zhu Z, Wahl S, Tian H . Apoptosis induction by a novel anti-prostate cancer compound, BMD188 (a fatty acid-containing hydroxamic acid), requires the mitochondrial respiratory chain. Cancer Res. 1999; 59(17):4343-55. View

15.

Beissbarth T, Speed T . GOstat: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics. 2004; 20(9):1464-5. DOI: 10.1093/bioinformatics/bth088. View

16.

Leys C, Nomura S, LaFleur B, Ferrone S, Kaminishi M, Montgomery E . Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery. 2006; 141(1):41-50. DOI: 10.1016/j.surg.2006.05.009. View

17.

Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M . Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics. 2002; 18 Suppl 1:S96-104. DOI: 10.1093/bioinformatics/18.suppl_1.s96. View

18.

Corazzari M, Lovat P, Armstrong J, Fimia G, Hill D, Birch-Machin M . Targeting homeostatic mechanisms of endoplasmic reticulum stress to increase susceptibility of cancer cells to fenretinide-induced apoptosis: the role of stress proteins ERdj5 and ERp57. Br J Cancer. 2007; 96(7):1062-71. PMC: 2360126. DOI: 10.1038/sj.bjc.6603672. View

19.

Buness A, Huber W, Steiner K, Sultmann H, Poustka A . arrayMagic: two-colour cDNA microarray quality control and preprocessing. Bioinformatics. 2004; 21(4):554-6. DOI: 10.1093/bioinformatics/bti052. View

20.

Lapointe J, Li C, Higgins J, van de Rijn M, Bair E, Montgomery K . Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A. 2004; 101(3):811-6. PMC: 321763. DOI: 10.1073/pnas.0304146101. View